Valo Therapeutics appoints Hemanshu Shah as Chief Business Officer

We see significant potential in working with oncolytic virus companies and Neo antigen-companies

Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US.

ValoTx's CEO, Paul Higham, said, "I am delighted to welcome Dr Hemanshu Shah as our CBO. Hemanshu brings a wealth of business development experience from an impressive career spanning corporate development, strategy, and marketing roles at Transgene, Astellas, Johnson & Johnson, and Bristol-Myers Squibb. He'll be making the most of the substantial business development opportunities represented by our unique cancer and infectious disease immunotherapy platforms. We see significant potential in working with oncolytic virus companies and Neo antigen-companies looking for an effective immune-stimulatory delivery to the tumour micro-environment."

ValoTx's CBO Hemanshu Shah, said, "I'm excited to join Valo's excellent team, and am looking forward to using my extensive oncology corporate development experience, including with oncolytic viruses, to help drive forward our innovative solutions to vaccines, immuno-oncology, and personalised cancer treatments."